Last updated
Revenue
R&D Expenses
Operating CF
Total Assets
Total Liabilities
Equity
Shares Out.
D/E Ratio
Dilution Watch
Financials
52W LOW $4.3152W HIGH $9.55
Volume
118.58 K
Value Traded
1.19 M
Short % Float
21.03%
Days to Cover
13.9
-3.87%Week
-22.71%1 Month
-21.98%3 Month
-5.51%6 Month
-31.49%5 Year
-31.49%All Time
Cash Data
- Monthly Burn
- Burn Trend
- Dilution Risk
- SEC Filing
Key Stats
Market Cap
140.28 M
EPS (TTM)
-0.22
P/E Ratio
-
Ent. Value
145.10 M
Total Shares
28.22 M
Float Shares
14.53 M
Insiders
48.50%
Institutions
36.20%
Upcoming Catalysts
FDA decisions, readouts and PDUFA dates · scored by probability of approval
| Catalyst | Drug / Treatment | Stage | Prob. of Approval | Description | Drug Type | Therapeutic Area | Source |
|---|---|---|---|---|---|---|---|
PDUFA 2026 | Example Drug Treatment for example condition requiring FDA review | Phase 3 | Small Molecule | Oncology | - |
PoA blends historical approval base rates, trial design score and FDA review track record.
DERM Catalyst Timeline
Dated clinical, regulatory and corporate events for Journey Medical Corporation
Catalyst Timeline
Dated clinical, regulatory & corporate events for Journey Medical Corporation
106Total events
0Upcoming
24Tier-1 (high impact)
2021 to 2026Coverage
Event history 50
●R&D DayPresentation
Journey Medical to participate in Lake Street BIG10 Conference (1x1 meetings)
▲Product LaunchEmrosiApprovedPost-Market
Contract with third major GPO for Emrosi
inflammatory lesions of rosaceasource ↗
▲Full ResultsEmrosiApprovedClinical Data
Publication of Phase 1 trial results assessing impact of Emrosi on microbial flora in healthy adults
rosaceasource ↗
●Quarterly UpdateCorporate
Conference call to discuss Q3 2025 financial results and business update
◆Oral PresentationPresentation
Journey Medical management to present at The ThinkEquity Conference
▲Poster PresentationDFD-29ApprovedPresentation
Poster presentation of pooled Phase 3 efficacy data for DFD-29 at 2025 Fall Clinical Dermatology Conference
rosaceasource ↗
▲Full ResultsDFD-29ApprovedClinical Data
Pooled analysis of Phase 3 trials MVOR-1 and MVOR-2 results presented
rosaceasource ↗
◆Oral PresentationPresentation
Journey Medical management to participate in 4th Annual ROTH Healthcare Opportunities Conference
▲Quarterly UpdateEmrosiApprovedCorporate
Expanded payer coverage for Emrosi to 65% of commercial lives
inflammatory lesions of rosaceasource ↗
▲Product LaunchEmrosiApprovedPost-Market
Emrosi first full quarter on market with $2.8M net sales
dermatological conditionssource ↗
▲Full ResultsEmrosiApprovedClinical Data
Phase 3 clinical trial results for Emrosi published in JAMA Dermatology
rosaceasource ↗
▲Product LaunchEmrosiApprovedPost-Market
Emrosi launched for rosacea
inflammatory lesions of rosaceasource ↗
▲Product LaunchEmrosiApprovedPost-Market
Direct promotion of Emrosi begins in early April
rosaceasource ↗
◆Timing GuidanceEmrosiApprovedPresentation
Full promotion of Emrosi expected in April 2025
rosaceasource ↗
▲Product LaunchEmrosiApprovedPost-Market
Initial distribution of Emrosi and first prescriptions filled
rosaceasource ↗
▲Full ResultsEmrosiApprovedClinical Data
Phase 3 clinical trial results for Emrosi published in JAMA Dermatology
rosaceasource ↗
▲Product LaunchEmrosiApprovedPost-Market
Launch of Emrosi for rosacea
inflammatory lesions of rosaceasource ↗
▲Oral PresentationEmrosiApprovedPresentation
Pooled Phase 3 efficacy analysis presented at Fall Clinical Dermatology Conference
inflammatory lesions of rosaceasource ↗
◆Product LaunchEmrosiApprovedPost-Market
Anticipated initial supply availability of Emrosi
rosaceasource ↗
▲FDA ApprovalEmrosiApprovedFDA Decision
FDA approval of Emrosi for inflammatory lesions of rosacea
inflammatory lesions of rosaceasource ↗
◆PDUFA DateDFD-29ApprovedRegulatory Filing
PDUFA goal date of November 4, 2024 for DFD-29
rosaceasource ↗
▲FDA ApprovalEmrosiApprovedFDA Decision
FDA approval of Emrosi (40 mg Minocycline Hydrochloride Modified-Release Capsules) for rosacea
rosaceasource ↗
Past FDA Catalysts and PDUFA Decisions
How DERM actually traded into and out of each decision
| Date | Drug | Catalyst | Stage | Reaction | Event Move % | Best Trade % |
|---|---|---|---|---|---|---|
| 2025-06-25 | Emrosi™ | Phase 3 data presentation | Phase 3 |
Reaction: 30 trading days around the event · Event Move: close to close on decision day · Best Trade: peak run-up from entry 10 days before the decision
Drug Pipeline Intelligence
Pipeline Score
Pipeline Value
Commercial Value
Valuation Signal
1
Drugs Scored
rNPV / MCap
Top Drug
Top 77%
Micro Cap(rank 506 of 657)
Percentile Rank
Commercial products (revenue basis: trailing 4 quarters of total revenue (10-K and 10-Q), to Jun 2026; product lines: last four quarters to Jun 2026 (10-K and 10-Q))
| Product | Revenue | Prior period | Change |
|---|---|---|---|
| Emrosi | |||
| Qbrexza | |||
| Accutane | |||
| Foam franchise products Amzeeq & Zilxi | |||
| Eurax |
| Drug | Indication | Phase | PTRS | rNPV | Status | Enroll | Velocity | Design | Est. Completion | ML Signal | Last Change |
|---|---|---|---|---|---|---|---|---|---|---|---|
| DFD-29 Fasting Small moleculeCompletedNCT05452785 | Undisclosed | Phase 1 | COMPLETED | 24 | May 25, 2022 | ||||||
| glycopyrronium Wipes Small moleculeMarketedNCT02530294 | Hyperhidrosis | Phase 3 | COMPLETED | 1,261 | Apr 1, 2016 | ||||||
| DFD-29 Small moleculeMarketedNCT05343455 | Papulopustular Rosacea | Phase 3 | COMPLETED | 653 | Jun 30, 2023 | ||||||
| Minocycline Small moleculeMarketedNCT05597462 | Rosacea | Phase 1 | COMPLETED | 60 | May 30, 2023 |
Clinical Trial Results
Readouts, endpoints and source filings for every DERM program
| Drug Name | Indication | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
| Emrosi | moderate-to-severe rosacea | Phase 1 | 2025-12-11 | 16 weeks; 60 healthy, adult subjects; 30 males and 30 females; 2:1 randomization between DFD-29 and placeboRead More | Journey Medical Corporation Announces Publication of Clinical Trial Results Assessing the Impact of Emrosi™ (DFD-29) on Microbial Flora of Healthy Adults in the Journal of Drugs in DermatologyRead More |
Inside Trades
| Insider | Side | Shares | Price | Value | Date |
|---|---|---|---|---|---|
| Toledano Miranda JayneDirector | Grant/Award | 50,000 168,618 held | $0.00 | 07/01/2026 |
Hedge Fund 13F Activity
Hedge Funds invested in DERM
| Fund | % of Portfolio | Current MV | Shares Owned | Activity |
|---|---|---|---|---|
| TANG CAPITAL MANAGEMENT LLC | 0.5 % (25 %) | 11.40 M | 1.61 M |
DERM Institutional Ownership Trends
DERM Short Interest
Shares sold short, counted twice a month.
21.03%
Short % of Float
of tradable shares sold short
3.1M
Shares Sold Short
+4.4% vs prior count
13.9 Very high
Days to Cover
trading days of normal volume to buy every short share back
219.7K
Avg Daily Volume
the average used for days to cover
Options Data
Option Volume
Open Interest
Call OI
Put OI
Put-Call Ratio
OI 30-day avg
Today vs avg
Option Volume
Call Vol
Put Vol
Put-Call Ratio
Vol 30-day avg
Today vs avg
Option Chain Statistics
| Expiry | Call Vol | Put Vol | Vol P/C | Call OI | Put OI | OI P/C | IV Call | IV Call OI-Wtd | IV Call Vol-Wtd | IV Put | IV Put OI-Wtd | IV Put Vol-Wtd |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-11-20 | ||||||||||||
Real-Time Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last | Vol | OI | Last | Vol | OI | |
| No data available | ||||||
Calls vs Puts by Expiry
CallsPutsLog scale
Competitive positioning
How DERM ranks across every disease it competes in
Competitive Position is a premium feature
See how DERM ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trialDERM News
DERM▼ -6.5%on this news
Journey Medical Corporation to Participate in September 2026 Investor Conferences
Journey Medical Corporation announced its participation in two investor conferences in September 2026. CEO Claude Maraoui will present at the Lake Street Capital Markets 10th Annual Best Ideas Growth Conference and the H.C. Wainwright 28th Annual Global Investment Conference. The company focuses on FDA-approved dermatological products and will provide a webcast of its presentation.
Read more →DERMJourney Medical Corporation Reports Second Quarter 2026 Financial Results and Recent Corporate Highlights
Journey Medical Corporation reported a 23% increase in total revenues for Q2 2026, reaching $18.5 million. Emrosi® contributed $8.1 million in revenue, reflecting strong demand and improved payer coverage. The company is moving towards profitability with a narrowed net loss of $0.3 million. A conference call is scheduled for further discussion.
Read more →DERMJourney Medical Corporation to Announce Second Quarter 2026 Financial Results on August 12, 2026
Journey Medical Corporation has announced that it will release its second quarter 2026 financial results on August 12, 2026. The company will hold a conference call and audio webcast at 4:30 p.m. ET on the same day. Interested parties can access the call via phone or through a live audio webcast on the company's website.
Read more →DERMJourney Medical Corporation to Participate in A.G.P.’s Annual Virtual Healthcare Conference
Journey Medical Corporation will participate in A.G.P.'s Annual Virtual Healthcare Conference on May 20, 2026. CEO Claude Maraoui is scheduled for a fireside chat at 5:00 PM ET. The company specializes in FDA-approved dermatological products and aims to enhance investor relations through this event.
Read more →DERMCorporation Reports First Quarter 2026 Financial Results and Recent Corporate Highlights
Journey Medical Corporation reported a 21% year-over-year increase in total revenues for Q1 2026, reaching $16.0 million. The company highlighted strong demand for its product Emrosi, which is establishing itself as a leading treatment for rosacea. With over $27 million in cash, Journey Medical positions itself well for continued growth and improved operational efficiency throughout the year. Upcoming events include a conference call scheduled for May 13, 2026, to discuss these results further.
Read more →DERMJourney Medical Corporation to Announce First Quarter 2026 Financial Results on May 13, 2026
Journey Medical Corporation will announce its first quarter 2026 financial results on May 13, 2026, after market close. A conference call is scheduled for the same day at 4:30 p.m. ET, where management will discuss the results and provide a corporate update. Interested parties can join the call via phone or a live audio webcast.
Read more →DERM▼ -5.2%on this news
Journey Medical Corporation Secures Contract with Third Major GPO for Emrosi™
Journey Medical Corporation has secured a contract with a third major group purchasing organization, expanding access to its product Emrosi™ to over 150 million commercial lives. This milestone is expected to enhance the drug's market presence and support its growth in prescription demand. The company aims to convert access into coverage and improve profitability through increased formulary adoption.
Read more →DERMCorporation Secures Contract with Third Major GPO for Emrosi Payer access for Emrosi expanded from
Journey Medical Corporation has secured a contract with its third major group purchasing organization (GPO), expanding payer access for its product Emrosi from approximately 100 million to over 150 million commercial lives in the U.S. The company reports that 85% of commercial lives now have access to Emrosi, which is approved for treating inflammatory lesions of rosacea in adults. The CEO expressed optimism about the growth potential for Emrosi, anticipating that increased formulary adoption will enhance profitability and reduce reliance on co-pay bridging programs. This development reflects Journey Medical's ongoing commitment to improving patient access to dermatological therapies.
Read more →DERM▼ -30%on this news
Journey Medical Corporation Reports Full-Year 2025 Financial Results and Recent Corporate Highlights
Journey Medical Corporation reported a successful financial year for 2025, with total revenues rising to $61.9 million, up from $56.1 million in 2024. The launch of Emrosi™ contributed significantly, generating $14.7 million in net revenues and achieving approximately 53,000 prescriptions filled. The company highlighted its expanding presence in medical dermatology and optimistic growth prospects for the future.
Read more →DERM▼ -5.1%on this news
Journey Medical Corporation to Announce Year End 2025 Financial Results on March 25, 2026
Journey Medical Corporation will announce its year-end 2025 financial results on March 25, 2026. A conference call will be held at 4:30 p.m. ET to discuss these results and provide a corporate update. Interested parties can join via phone or access a live audio webcast on the company's website.
Read more →DERMJourney Medical Corporation Announces Publication of Clinical Trial Results Assessing the Impact of Emrosi™ (DFD-29) on Microbial Flora of Healthy Adults in the Journal of Drugs in Dermatology
Journey Medical Corporation announced the publication of Phase 1 clinical trial results for Emrosi (DFD-29), demonstrating its safety and lack of impact on microbial flora in healthy adults. The study confirmed that Emrosi can be administered for 16 weeks without affecting skin, gastrointestinal, or vaginal microbiota. These findings support Emrosi's use as a treatment for moderate-to-severe rosacea.
Read more →DERM▼ -15.3%on this news
Journey Medical Corporation Reports Third Quarter 2025 Financial Results and Recent Corporate Highlights
Journey Medical reported third quarter net revenues of $17.6 million, a 21 percent increase from the prior year. Emrosi net revenues reached $4.9 million, while total prescriptions for the drug rose 146 percent compared to the second quarter. The company posted a net loss of $2.3 million for the period. Cash and cash equivalents stood at $24.9 million at the end of the quarter.
Read more →DERMJourney Medical Corporation Reports Combined Emrosi™ (DFD-29) Phase 3 Clinical Trial Efficacy Data Analysis Presented at the 2025 Fall Clinical Dermatology Conference
Journey Medical Corporation presented promising efficacy data for DFD-29, an oral formulation of minocycline, at the 2025 Fall Clinical Dermatology Conference. The Phase 3 trials demonstrated significant improvements in treatment success rates and reduction of inflammatory lesions in rosacea patients compared to both placebo and Oracea. The results highlight Emrosi's potential as a leading treatment option in dermatology.
Read more →DERMJourney Medical Corporation to Participate in October 2025 Investor Conferences
Journey Medical Corporation announced its participation in two investor conferences scheduled for October 2025. The events include the 4th Annual ROTH Healthcare Opportunities Conference and the ThinkEquity Conference, both taking place in New York City. This engagement reflects the company's ongoing efforts to connect with investors and promote its FDA-approved dermatological products.
Read more →DERMJourney Medical Corporation to Present at the Emerging Growth Conference
Journey Medical Corporation (DERM) will present a corporate overview at the Emerging Growth Conference on August 20, 2025. CEO Claude Maraoui will lead the presentation, which will be conducted virtually. The company specializes in FDA-approved prescription products for dermatological conditions and aims to enhance its market presence through this event.
Read more →DERM▲ +8.5%on this news
Journey Medical Corporation Reports Second Quarter 2025 Financial Results and Recent Corporate Highlights
Journey Medical Corporation reported strong financial results for the second quarter of 2025, with total revenues of $15 million, including net sales from its newly launched product Emrosi amounting to $2.8 million. The quarter marks the first full period since Emrosi entered the market, which has seen a positive reception from physicians and payers. Additionally, the company announced its inclusion in the Russell 2000 and Russell 3000 Indexes, potentially increasing its visibility. A conference call is scheduled to discuss these results and future plans.
Read more →DERMJourney Medical Corporation to Ring Nasdaq Stock Market Closing Bell on August 11
Journey Medical Corporation is set to ring the Nasdaq closing bell on August 11, 2025, celebrating its four-year anniversary as a publicly traded company. The event coincides with the commercial launch of Emrosi, a new treatment for rosacea. The CEO highlighted the company's progress and confidence in future profitability.
Read more →DERMJourney Medical Corporation to Announce Second Quarter 2025 Financial Results on August 12, 2025
Journey Medical Corporation has announced that it will release its second quarter 2025 financial results on August 12, 2025. The company will conduct a conference call and audio webcast at 4:30 p.m. ET on the same day. Interested parties can participate by dialing in or accessing the webcast through the company's website.
Read more →DERMJourney Medical Corporation Announces Expanded Payer Coverage for Emrosi™
Journey Medical Corporation has announced that payer coverage for its rosacea treatment, Emrosi, has expanded to 65% of commercial lives in the U.S., up from 29% in May 2025. This increase is expected to drive further growth in prescription demand. The company's CEO expressed optimism about the product's adoption and its potential to become the standard of care for rosacea.
Read more →DERM▲ +8.9%on this news
Journey Medical to Join Russell 2000 and Russell 3000 Indexes
Journey Medical Corporation (Nasdaq: DERM) announced its inclusion in the Russell 2000 and Russell 3000 Indexes effective June 27, 2025. This move is expected to enhance the company's visibility among investors. Journey Medical's recent product, Emrosi, designed for treating inflammatory lesions of rosacea, is reportedly performing well in the market. The company anticipates that 2025 could be a pivotal year for its growth and expansion.
Read more →About Journey Medical Corporation
Headquarters9237 E VIA DE VENTURA BLVD., SUITE 105, SCOTTSDALE, AZ, 85258
BIOPHARMAWATCH ELITE PLUS
Trade the next DERM catalyst before the market reprices
Every FDA decision, PoA score, 13F move and dilution flag on this page, for 1,100+ biotech tickers. From $19/mo billed annually.
Cancel anytime